Although some studies have demonstrated that stimulation of NKG2D can trigger activation of NK cells even in the absence of FcγR (45), we observed that in FcγR-deficient NK cells the exposure to cetuximab and radiated tumor cells did not effectively activate IFNγ expression, despite up-regulation of NKG2D ligands on the radiated tumor cells. The gene discussed is KLRK1; the disease is neoplasm.